Patents by Inventor Shaun FONTAINE

Shaun FONTAINE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNERGISTIC CANCER TREATMENT
    Publication number: 20240082436
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Application
    Filed: July 11, 2023
    Publication date: March 14, 2024
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun FONTAINE
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20230321286
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: March 7, 2023
    Publication date: October 12, 2023
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
  • IMPROVED CONJUGATION LINKERS
    Publication number: 20220280654
    Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 8, 2022
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Brian HEARN, Shaun FONTAINE, Eric L. SCHNEIDER
  • SYNERGISTIC CANCER TREATMENT
    Publication number: 20200397778
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 24, 2020
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun FONTAINE
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20200360545
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 19, 2020
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY